报价延迟最少15分钟:2025/07/21 07:02 EDT
盘前时段
|
||||
|
545.29 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
542.52
|
|
|
| 价值评估 |
|
盈利(现时/预测)
39.34/40.04
|
|
企业价值
62.09B
|
| 资产负债 |
|
每股账面净值
272.19
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
14.20B
|
|
每股收益
121.31
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 07:02 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
